Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | BCL2A1 | Q16548 | 8/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | BID | P55957 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7515669 | 0.85 | P2RX7 (0.48) | HRH3P2RX7 | |
| SCHEMBL7556147 | 0.83 | P2RX7 (0.52) | HRH3P2RX7NPC1RAB9APOLB | |
| SCHEMBL7660485 | 0.79 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL7660490 | 0.79 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL5398913 | 0.75 | P2RX7 (0.63) | HRH3P2RX7 | |
| SCHEMBL7518675 | 0.74 | ESRRB (0.49) | P2RX7NPC1RAB9APOLBHPGD | |
| SCHEMBL21434774 | 0.73 | KDM4E (0.55) | HRH3P2RX7NPC1RAB9AHPGD | |
| SCHEMBL7559238 | 0.73 | HPGD (0.46) | P2RX7NPC1RAB9APOLBHPGD | |
| SCHEMBL7560739 | 0.70 | P2RX7 (0.55) | P2RX7POLBHPGD | |
| SCHEMBL7592357 | 0.70 | HPGD (0.54) | P2RX7NPC1RAB9APOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171432-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061569-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | disclosed |